20 Apr '17
Scientists at the Tomsk State University (TSU)’s cell and molecular biomedicine lab and their colleagues at the local Research Institute of Cardiology are looking into ways the human immune system responds after myocardial infarction which could trigger heart failure. A new method is under way to assess immune inflammations in the human heart, a way of losing no time in identifying patients who need extra therapy and ongoing monitoring.
As Alexandra Gombozhapova, a project developer, explained, she knows of no method elsewhere in Russia of assessing such post-infarction inflammations directly inside the heart. The collaborative team is looking for process-specific biomarkers and their combinations in immune cells called macrophages. In their research, the scientists take cardiac tissue from patients who died of myocardial infarction and its complications, and use biomarkers to identify and quantify various types of macrophages, thus enabling the assessment of the type of inflammation.
“In our effort, we have plans to look into the “behavior” of six biomarkers in 40-to-60 patients, and use results to put together diagnostics systems containing the biomarkers and their combinations, which would make it possible in future to waste no time identifying patients at risk and preventing the development of dangerous complications, including heart failure,” Ms. Gombozhapova said.
As the research continues, the team hopes to be able to look at broader issues and not only identify intra-cardiac inflammations but also study the macrophages as possible therapeutic targets.